Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242


Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.

Wei F, Wang H, Chen X, Li C, Huang Q.

Cancer Biol Ther. 2014 Oct;15(10):1358-66. doi: 10.4161/cbt.29842. Epub 2014 Jul 14.


E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.

Wakayama M, Abei M, Kawashima R, Seo E, Fukuda K, Ugai H, Murata T, Tanaka N, Hyodo I, Hamada H, Yokoyama KK.

Clin Cancer Res. 2007 May 15;13(10):3043-50.


The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.

Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, Wang YG, Jia XY, Liu XY.

Cancer Biol Ther. 2010 Aug 1;10(3):242-50. Epub 2010 Aug 10.


A novel immunocompetent murine tumor model for the evaluation of RCAd-enhanced RDAd transduction efficacy.

Wang H, Wei F, Zhang J, Wang F, Li H, Chen X, Xie K, Wang Y, Li C, Huang Q.

Tumour Biol. 2012 Aug;33(4):1245-53. doi: 10.1007/s13277-012-0374-7. Epub 2012 May 25.


Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.

Wang H, Wei F, Li H, Ji X, Li S, Chen X.

Int J Mol Med. 2013 Feb;31(2):377-85. doi: 10.3892/ijmm.2012.1197. Epub 2012 Nov 29.


E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.

Fukuda K, Abei M, Ugai H, Kawashima R, Seo E, Wakayama M, Murata T, Endo S, Hamada H, Hyodo I, Yokoyama KK.

Cancer Gene Ther. 2009 Feb;16(2):126-36. doi: 10.1038/cgt.2008.67. Epub 2008 Sep 26.


E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.

Kim J, Kim JH, Choi KJ, Kim PH, Yun CO.

Hum Gene Ther. 2007 Sep;18(9):773-86.


Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.

Kim J, Cho JY, Kim JH, Jung KC, Yun CO.

Cancer Gene Ther. 2002 Sep;9(9):725-36.


HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.

Xu HN, Huang WD, Cai Y, Ding M, Gu JF, Wei N, Sun LY, Cao X, Li HG, Zhang KJ, Liu XR, Liu XY.

Mol Cancer. 2011 Nov 1;10:133. doi: 10.1186/1476-4598-10-133.


A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.

Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.

Cancer Res. 2001 Sep 1;61(17):6428-36.


A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.

Yamasaki Y, Tazawa H, Hashimoto Y, Kojima T, Kuroda S, Yano S, Yoshida R, Uno F, Mizuguchi H, Ohtsuru A, Urata Y, Kagawa S, Fujiwara T.

Eur J Cancer. 2012 Sep;48(14):2282-91. doi: 10.1016/j.ejca.2011.12.020. Epub 2012 Jan 13.


Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.

Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q.

Clin Cancer Res. 2006 Nov 1;12(21):6523-31.


Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.

Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D.

Gene Ther. 2005 Sep;12(17):1333-46.


An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.

Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.

Cancer Res. 2003 Apr 1;63(7):1490-9.


Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53.

Sauthoff H, Pipiya T, Chen S, Heitner S, Cheng J, Huang YQ, Rom WN, Hay JG.

Cancer Gene Ther. 2006 Jul;13(7):686-95. Epub 2006 Feb 10.


Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.

Doloff JC, Waxman DJ, Jounaidi Y.

Hum Gene Ther. 2008 Dec;19(12):1383-400. doi: 10.1089/hum.2008.056.


E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.

Fukuda K, Abei M, Ugai H, Seo E, Wakayama M, Murata T, Todoroki T, Tanaka N, Hamada H, Yokoyama KK.

Cancer Res. 2003 Aug 1;63(15):4434-40.


Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.

Doloff JC, Jounaidi Y, Waxman DJ.

Cancer Gene Ther. 2011 Mar;18(3):153-66. doi: 10.1038/cgt.2010.52. Epub 2010 Sep 24. Erratum in: Cancer Gene Ther. 2011 Mar;18(3):228. Jounaidi, Y [added].


Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.

Yoon AR, Kim JH, Lee YS, Kim H, Yoo JY, Sohn JH, Park BW, Yun CO.

Hum Gene Ther. 2006 Apr;17(4):379-90.


Supplemental Content

Support Center